Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete-Choice Experiment (OPTIC).
Individuals with overweight or obesity prefer medications that offer effective weight loss and cardiovascular benefits, particularly those that can be taken orally.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpusSummary and findings
This study evaluated preferences for obesity medications among US adults with overweight or obesity. Participants completed a discrete-choice experiment comparing hypothetical medication profiles based on various attributes. The findings indicated a strong preference for oral medications over injections.
Abstract
<h4>Aims</h4>To evaluate the relative importance of attributes driving obesity medication (OM) choice and preferences among individuals with overweight or obesity.<h4>Materials and methods</h4>US adults with obesity or overweight and ≥ 1 obesity-related complication completed an online survey including a discrete-choice experiment (DCE) in October-November 2025. In the DCE, participants chose between 2 hypothetical, experimentally designed OM profiles with attributes/levels related to efficacy, cardiovascular (CV) risk reduction, side effects, administration (route/frequency), and dosing instruction requirements. In a fixed-choice comparison, participants chose between 2 predefined oral OM profiles. Relative preference weights for the DCE attribute levels were estimated using a random-parameters logit model to estimate attribute importance, tradeoffs, and predicted treatment choice.<h4>Results</h4>Among 800 participants (400 OM-naïve/400 OM-experienced, 400 injection-naïve/400 injection-experienced), the most important attributes were route of administration, average weight-loss percentage, CV risk reduction, and the proportion of people achieving ≥ 20% weight loss. Dosing instructions had the lowest relative importance. There was a preference for 1 OM profile (Treatment A-a hypothetical oral semaglutide-like profile) over the alternative OM profile (Treatment B-a hypothetical orforglipron-like profile), according to the responses from the DCE (84.2% vs. 15.8%) and the fixed-choice question (90.0% vs. 10.0%). Only 23.4% indicated that taking an OM treatment on an empty stomach and waiting 30 min to eat would be disruptive to their lives. Most (73.3%) OM-naïve participants were open to taking an oral OM.<h4>Conclusions</h4>Individuals with overweight or obesity prioritise weight-loss efficacy, CV risk reduction, and oral administration in OM treatment decisions; dosing instruction requirements were of low importance.
Background
This paper addresses the preferences for obesity medications among individuals with overweight or obesity, a population that often faces challenges in treatment adherence. Prior research has indicated that factors such as efficacy and side effects significantly influence medication choice. Understanding these preferences is crucial for developing effective obesity treatment strategies and improving patient outcomes.
Methods
The study utilized a discrete-choice experiment (DCE) involving 800 US adults with obesity or overweight and at least one obesity-related complication. Participants were divided into groups based on their previous experience with obesity medications. The DCE assessed preferences for various medication attributes, including efficacy, cardiovascular risk reduction, and administration route.
Results
The primary finding indicated that 84.2% of participants preferred Treatment A (hypothetical oral semaglutide-like profile) over Treatment B (hypothetical orforglipron-like profile). The most important attributes influencing preferences were route of administration, average weight-loss percentage, and cardiovascular risk reduction. Dosing instructions were deemed the least important.
Interpretation
These findings align with previous literature emphasizing the importance of efficacy and administration route in medication preferences. The effect size regarding preference for oral administration over injections may be clinically meaningful, as it suggests a potential barrier to treatment adherence. However, the reliance on hypothetical scenarios and self-reported data introduces confounding factors that may limit the generalizability of the results.
Key findings
- 84.2% preferred Treatment A (hypothetical oral semaglutide-like profile) over Treatment B (hypothetical orforglipron-like profile).
- 90.0% chose Treatment A over Treatment B in a fixed-choice question.
- 73.3% of OM-naïve participants were open to taking an oral obesity medication.
- Only 23.4% indicated that taking an obesity medication on an empty stomach and waiting 30 minutes to eat would be disruptive.
Limitations
- self-reported preferences may not reflect actual medication adherence
- hypothetical scenarios may not predict real-world behavior
- no long-term follow-up to assess actual treatment outcomes